R-Meth

Diclofenac Orodispersible Tablets

Bisoprolol Fumarate Tablets USP 2.5mg

Buprenorphine Sublingual Tablets IP

Calcium Dobesilate Monohydrate Capsules 500mg

Apomorphine 2mg Sublingual Tablet

1. Reduces Cravings For Alcohol 2. Rapid Detoxification & quick onset of action 3. Reduces risk of Relapse 4. Effective in both opioid & alcohol de- addiction

Rufenyl Injection - 1. Synthetic opioid 50-100 times more potent than morphine2. Can be used before, during, and after surgery to manage pain3. Can be used to patients who had developed tolerance to opiates 4. Often used in emergency rooms to manage pain from traumatic injuries Rufenyl Patch-1. Improves...

1.Better Patient Compliance 2.Rigorousely Tested by AIIMS (Delhi) 3.Faster Onset Of Action Addnok-N(R) is an opioid medication known for its ceiling effect, which enhances safety in administration for patients. The product is available in the following compositions: Bu...

Rusan Pharma Ltd offers a wide range of tablets which includes bioran tablet. Package size/ Form: N.100 tablet. Contact us for more information.

2baconil® Nicotine Gum – Tobacco Cessation Support

Available Strengths: 2 mg and 4 mg
Flavors: Mint
Manufacturer: Rusan Pharma Ltd.

Product Overview

2baconil® Nicotine Gum is a Nicotine Replacement Therapy (NRT) designed to help individuals quit smoking ...

2baconil® Patch is a nicotine transdermal patch that helps in quitting smoking / smokeless tobacco using the principle of Nicotine Replacement Therapy (NRT). It is a unique 24 hr patch with SmartTime Release® Technology that helps control the urge to consume tobacco all day long. 2baconil® braces...

Naltrexone Tablets IP 50mg

Rusan Pharma Ltd. has achieved two major regulatory milestones for its advanced manufacturing facility located in the Kandla Special Economic Zone (SEZ) Unit-II in Gujarat, India. The facility, which specializes in high-speed production of transdermal patches and oral films, has received Good Manufacturing Practice (GMP) certification from Australia’s Therapeutic Goods Administration (TGA) and a GMP extension from Brazil’s Health Regulatory Agency, ANVISA.

The TGA certification marks a pivotal step in Rusan Pharma’s expansion into the Australian market. Following a rigorous inspection, the facility was granted A1 GMP compliance, validating its capability to produce specialized drug delivery systems such as Buprenorphine, Nicotine Transdermal Patches, and Buprenorphine+Naloxone Sublingual Films. These products are designed to address critical medical needs in pain management and addiction treatment. This is the second time the TGA has approved the Kandla Unit-II faci...

Corporate+ Font Resize -Rusan Pharma achieves dual GMP milestones from TGA, Australia and ANVISA, for its manufacturing facilityOur Bureau, Mumbai
Friday, December 13, 2024, 16:45 Hrs  [IST]Rusan Pharma Ltd, a leading global pharmaceutical company specialising in addiction treatment and pain management, has announced two significant milestones for its state-of-the-art dedicated high-speed transdermal patch and oral film manufacturing facility, located in the Kandla Special Economic Zone (SEZ)-UNIT-II (Gujarat, India) (“KDL-2”). 

We are happy to announce the approval of our first finished dosage formulation (FDF) in Canada - RPC-Naltrexone Film-Coated Tablets (50 mg) (DIN: 02558343), through our subsidiary Rusan Pharma Canada Inc (RPCI).Rusan's Active Pharmaceutical Ingredient (API) and FDF manufacturing facilities are Health Canada GMP approved. With our integration to in-house manufacturing of the API - Naltrexone Hydrochloride, we plan to ensure that product has a robust supply chain and has a pan-Canadian reach.With this approval, we are excited to launch Rusan's global initiative and mission "FREEDOM FROM DEPENDENCE (PROJECT FREEDENCE)". Under this mission, we plan to become a global leader in addiction care (drugs, alcohol and tobacco), by introducing globally accepted treament standards such as Naltrexone Tablets, Buprenorphine+Naloxone Sublingual Tablets and films, Methadone Oral Solution, Nicotine gums, oral films and transdermal patches and other innovative delivery solutions.I am excited th...

RUSAN PHARMA PRIVATE LIMITED, an Indian pharmaceutical company specializing in addiction treatment and pain management, announced that its Active Pharmaceutical Ingredient (API) facility in Ankleshwar, Gujarat, received Good Manufacturing Practice (GMP) approval from the USFDA on May 29, 2024, following a rigorous inspection. This approval marks a significant milestone, enabling Rusan to expand into the US API market, particularly for niche APIs like Eflornithine and Nalmefene, while planning to add more APIs to its portfolio. Rusan Pharma’s Managing Director, Dr. Kunal Saxena, emphasized the company’s commitment to quality and global expansion. The USFDA approval complements Rusan's existing GMP certifications from Health Canada, the EU, and Brazil’s ANVISA, and aligns with the company’s vision to be a leader in addiction treatment and pain management.